Novel Strategies in the Prevention/Treatment of Colorectal Cancer: 2nd Edition

Dear Colleagues,

This Special Issue is the second edition of a previous one on the topic of “Novel Strategies in the Prevention/Treatment of Colorectal Cancer” (https://www.mdpi.com/journal/cancers/special_issues/8UD4M2OMJR).

The signaling pathways dysregulated during canonical CRC initiation and progression are potential targets for both chemoprevention and cancer treatment. However, the Wnt, P53, and TGF-b pathways have not been fully exploited for drug development to either reduce CRC incidence or improve treatment, in part because of their key role in normal tissue homeostasis and the difficulty in developing drugs for these targets. Chemoprevention of CRC for high-risk individuals (e.g., Lynch syndrome) is still under development, but with promising preclinical results targeting mediators of inflammation, such as COX-2 and other targets, such as HMG-CoA reductase. Cancer interception is a new strategy for which target pathway identification is in its infancy. In contrast, adjuvant chemotherapy for locally advanced CRC uses fluoropyrimidine combinations such as FOLFOX to target TS and DNA damage, while treatment of metastatic disease may use these same combinations of drugs or antibodies targeting EGFR, VEGF, and, more recently, BRAF and KRAS, but innovative strategies continue to be developed to personalize the therapeutic approach.

The current Special Issue will focus on original research articles and comprehensive reviews illuminating the most recent advances in understanding molecular pathways of CRC initiation and progression that are amenable to therapeutic intervention. Studies identifying and validating novel pathways or targets for preventing or treating CRC are of special interest; however, innovative approaches for well-validated targets for CRC therapy, including TS, DNA topoisomerase 1, EGFR, and other targets, are also of interest. Innovative approaches to use chemotherapy in combination with immunotherapy and for the development of cancer vaccines are of special interest.

Prof. Dr. William H. Gmeiner
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.